In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans von Clémence, Chevalier, Fouqueray, Pascale, Sébastien, Bolze

Volltext

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes von Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.

Volltext

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action von Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E

Volltext

Imeglimin: A Clinical Pharmacology Review von Chevalier, Clémence, Fouqueray, Pascale, Bolze, Sébastien

Volltext

Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects von Fouqueray, Pascale, Perrimond-Dauchy, Sandrine, Bolze, Sébastien

Volltext

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects von Fouqueray, Pascale, Chevalier, Clémence, Bolze, Sébastien

Volltext

Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment von Chevalier, Clémence, Dubourg, Julie, Bolze, Sébastien, Fouqueray, Pascale

Volltext

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats von Hallakou‐Bozec, Sophie, Kergoat, Micheline, Moller, David E., Bolze, Sébastien

Volltext

Lack of Drug–Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers von Chevalier, Clémence, Perrimond-Dauchy, Sandrine, Dubourg, Julie, Fouqueray, Pascale, Bolze, Sébastien

Volltext

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity von Theurey, Pierre, Thang, Carole, Pirags, Valdis, Mari, Andrea, Pacini, Giovanni, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Fouqueray, Pascale

Volltext

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes von Tomita, Yoshiko, Hansson, Emma, Mazuir, Florent, Wellhagen, Gustaf J, Ooi, Qing Xi, Mezzalana, Enrica, Kitamura, Atsushi, Nemoto, Daisuke, Bolze, Sébastien

Volltext

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin von Theurey, Pierre, Vial, Guillaume, Fontaine, Eric, Monternier, Pierre‐Axel, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Hallakou‐Bozec, Sophie

Volltext

In Vitro Primary Human and Animal Cell-Based Blood−Brain Barrier Models as a Screening Tool in Drug Discovery von Lacombe, Olivier, Videau, Orianne, Chevillon, Delphine, Guyot, Anne-Cécile, Contreras, Christelle, Blondel, Sandrine, Nicolas, Laurence, Ghettas, Aurélie, Bénech, Henri, Thevenot, Etienne, Pruvost, Alain, Bolze, Sébastien, Krzaczkowski, Lucie, Prévost, Colette, Mabondzo, Aloïse

Volltext

Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs von Fossati, Lina, Dechaume, Rachel, Hardillier, Emmanuel, Chevillon, Delphine, Prevost, Colette, Bolze, Sébastien, Maubon, Nathalie

Volltext

Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model von Vial, Guillaume, Chauvin, Marie-Agnès, Bendridi, Nadia, Durand, Annie, Meugnier, Emmanuelle, Madec, Anne-Marie, Bernoud-Hubac, Nathalie, Pais de Barros, Jean-Paul, Fontaine, Éric, Acquaviva, Cécile, Hallakou-Bozec, Sophie, Bolze, Sébastien, Vidal, Hubert, Rieusset, Jennifer

Volltext

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1) von Harrison, Stephen A., Thang, Carole, Bolze, Sébastien, Dewitt, Sheila, Hallakou-Bozec, Sophie, Dubourg, Julie, Bedossa, Pierre, Cusi, Kenneth, Ratziu, Vlad, Grouin, Jean-Marie, Moller, David E., Fouqueray, Pascale

Volltext

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus von Dubourg, Julie, Perrimond-Dauchy, Sandrine, Felices, Mathieu, Bolze, Sébastien, Voiriot, Pascal, Fouqueray, Pascale

Volltext

Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents von Perry, Rachel J, Cardone, Rebecca L, Petersen, Max C, Zhang, Dongyan, Fouqueray, Pascale, Hallakou-Bozec, Sophie, Bolze, Sébastien, Shulman, Gerald I, Petersen, Kitt Falk, Kibbey, Richard G

Volltext

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy von Monternier, Pierre-Axel, Parasar, Parveen, Theurey, Pierre, Gluais Dagorn, Pascale, Kaur, Navtej, Nagaraja, Tavarekere N, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Singh, Jaspreet, Hallakou-Bozec, Sophie

Volltext

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity von Jacques, Vincent, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Czarnik, Anthony W., Divakaruni, Ajit S., Fouqueray, Pascale, Murphy, Anne N., Van der Ploeg, Lex H.T., DeWitt, Sheila

Volltext